Respiratory Synctial Virus Infections
Conditions
Keywords
Reactogenicity, Safety, Respiratory syncytial virus (RSV), Vaccine, Immunogenicity
Brief summary
The purpose of this first time in human (FTiH) study is to assess the safety, reactogenicity and immunogenicity of 2 doses of the RSV investigational vaccine, when administered intramuscularly according to a 0, 1 month schedule, in healthy adults aged 18 to 45 years.
Interventions
BIOLOGICALGSK3389245A_LD GROUP
2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
BIOLOGICALGSK3389245A_HD GROUP
2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
BIOLOGICALBexsero
2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
DRUGPlacebo
2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol * Written informed consent obtained from the subject prior to performing any study specific procedure * A male or female between, and including, 18 and 45 years of age at the time of first vaccination * Healthy subjects as established by medical history and clinical examination before entering into the study * Female subjects of non-childbearing potential may be enrolled in the study * Female subjects of childbearing potential may be enrolled in the study, if the subject: * has practiced adequate contraception for 30 days prior to vaccination, and * has a negative pregnancy test on the day of vaccina-tion, and * has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series
Exclusion criteria
* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product * Use of any investigational or non-registered product other than the study vaccines during the period starting 30 days before the first dose of study vaccines, or planned use during the study period * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to study vaccination, or planned administration during the study period * Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the first dose and ending 30 days after the last dose of vaccine administration, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before the first dose and ≥ 15 days after the last dose of study vaccine * Administration of immunoglobulins and/or any blood products during the period starting 3 months before the first dose of study vaccines or planned administration during the study period * Blood donation within 4 months prior to study entry or planned blood donation at any time during the study * Previous vaccination against RSV * Previous vaccination with a recombinant simian or human adenoviral vaccine * Previous Bexsero or other vaccination against Neisseria meningitidis serogroup B * History of or current autoimmune disease * Family history of congenital or hereditary immunodefi-ciency * History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccines. * History of any neurological disorders or seizures * History of transient thrombocytopenia or neurological complications following any prior vaccination * Hypersensitivity to latex * Hypersensitivity to Bexsero's active substances or to any of its excipients * Allergic reaction to kanamycin * Any medical condition that in the judgment of the investi-gator would make intramuscular injection unsafe * Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination * Acute disease and/or fever at the time of enrolment * Acute or chronic, clinically significant pulmonary, cardio-vascular, hepatic or renal functional abnormality, as de-termined by physical examination or laboratory screening tests * Malignancy within previous 5 years or lymphoproliferative disorders * Any clinically significant or any ≥ Grade 2 haematological laboratory abnormality * Body mass index \> 40 kg/m2 * Current alcohol and/or drug abuse * Pregnant or lactating female * Any other condition that the investigator judges may interfere with study procedures or findings * Planned move to a location that will prohibit participating in the trial until study end
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | From Day 0 to Day 360 | Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. |
| Number of Subjects With Solicited Local Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. All solicited local symptoms are considered as related to the vaccination. |
| Number of Subjects With Solicited General Symptoms | During the 7-day (Days 0-6) post-vaccination period following each dose and across doses | Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\] gastrointestinal symptoms (gastro) \[nausea, vomiting, diarrhoea and/or abdominal pain\] and headache. Any = occurrence of the symptom regardless of intensity grade and relationship to the vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination. |
| Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | At Day 1 | Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cells \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 1 (U-B), unknown at baseline and within at Day 1 (U-W), unknown at baseline and above at Day 1 (U-A), below at baseline and below at Day 1 (B-B), below at baseline and within at Day 1 (B-W), below at baseline and above at Day 1(B-A), within at baseline and below at Day 1 (W-B), within at baseline and within at Day 1(W-W), within at baseline and above at Day 1(W-A), above at baseline and below at Day 1(A-B), above at baseline and within at Day 1 (A-W), above at baseline and above at Day 1(A-A) |
| Number of Subjects With Haematological and Biochemical Results by Maximum Grade | From Day 1 to Day 60 | Parameters analysed were ALT, activated partial thromboplastin time \[APTT\], AST, total bilirubin \[TB\], CRE, EOS, haemoglobin decrease \[HgD\], LYM, NEU, platelets \[PLA\], PT, white blood cells decrease \[WBCD\] and white blood cells increase \[WBCI\]. Assessed grades were: Unknown \[UG\], grade 0 \[G0\] = no grade, 1 \[G1\] = mild grade, 2 \[G2\] = moderate grade, 3 \[G3\] = severe grade, 4 \[G4\] = potentially life threatening and overall grading \[GTotal\]. Parameter grade combinations expressed were: parameter plus UG/G0/1/2/3/4/Total at baseline versus grading G0/1/2/3/4/Total from Day 1 up to Day 60, for the same parameter, e.g. ALT G0-G2. |
| Number of Subjects With Unsolicited Adverse Events (AEs) | During the 30-day (Days 0-29) post-vaccination period | An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | At pre-vaccination (Day 0), post-Dose 1 (Day 30) and post-Dose 2 (Day 60) | Serum neutralizing antibody titers were reported as the inverse of the serum dilution which yielded a 60% reduction in the number of viral plaques compared to virus control without serum (Estimated Dilution: ED60). Antibody titers were expressed as Geometric Mean Titers (GMTs). |
| Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | At pre-vaccination (Day 0), post-Dose 1 (Day 30) and post-Dose 2 (Day 60) | Pre-defined cut-off values was higher than or equal to (≥) 8 ED60. |
| Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | At pre-vaccination (Day 0) and post-Dose 1 (Day 7, Day 30) and post-Dose 2 (Day 37, Day 60) | Interferon-gamma specific T-cells, expressed as T-cells per (/) million cells, were determined by the Enzyme Linked ImmunoSpot (ELISpot) assay. |
| Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | At pre-vaccination (Day 0) and post-Dose 1 (Day 7, Day 30) and post-Dose 2 (Day 37, Day 60) | IgG/IgA antibody specific B-cells/ expressed as B-cells per million cells, were determined by the ELISpot assay. |
| Number of Subjects With Haematological and Biochemical Results by Maximum Grade | From Day 1 up to Day 360 | Parameters analysed were ALT, activated partial thromboplastin time \[APTT\], AST, total bilirubin \[TB\], CRE, EOS, haemoglobin decrease \[HgD\], LYM, NEU, platelets \[PLA\], PT, white blood cells decrease \[WBCD\] and white blood cells increase \[WBCI\]. Assessed grades were: Unknown \[UG\], grade 0 \[G0\] = no grade, 1 \[G1\] = mild grade, 2 \[G2\] = moderate grade, 3 \[G3\] = severe grade, 4 \[G4\] = potentially life threatening and overall grading \[GTotal\]. Parameter grade combinations expressed were: parameter plus UG/G0/1/2/3/4/Total at baseline versus grading G0/1/2/3/4/Total from Day 1 up to Day 360, for the same parameter, e.g. ALT G0-G2. |
Countries
United Kingdom
Participant flow
Pre-assignment details
Out of 73 subjects originally enrolled in this study, only 72 subjects received the study vaccination and were hence included in the Total Vaccinated Cohort.
Participants by arm
| Arm | Count |
|---|---|
| GSK3389245A_LD Group Subjects received 2 doses of the investigational GSK3389245A low dose (LD) vaccine, one month apart, at Day 0 and Day 30. | 7 |
| GSK3389245A_HD Group Subjects received 2 doses of the investigational GSK3389245A high dose (HD) vaccine, one month apart, at Day 0 and Day 30. | 31 |
| Placebo Group Subjects received 2 doses of placebo vaccine, one month apart, at Day 0 and Day 30. | 19 |
| Bexsero Group Subjects received 2 doses of the active control vaccine, one month apart, at Day 0 and Day 30. | 15 |
| Total | 72 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 0 | 3 | 3 | 0 |
| Overall Study | Migrated/moved from study area | 1 | 5 | 1 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | GSK3389245A_LD Group | Total | Bexsero Group | Placebo Group | GSK3389245A_HD Group |
|---|---|---|---|---|---|
| Age, Continuous | 32.9 Years STANDARD_DEVIATION 8.2 | 30.8 Years STANDARD_DEVIATION 8.3 | 29.5 Years STANDARD_DEVIATION 7.6 | 31.3 Years STANDARD_DEVIATION 8.6 | 30.6 Years STANDARD_DEVIATION 8.7 |
| Race/Ethnicity, Customized Geographic ancestry Asian - Central/South Asian Heritage | 0 Participants | 4 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - East Asian Heritage | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - Japanese Heritage | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Geographic ancestry Asian - South East Asian Heritage | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Geographic ancestry Other | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Geographic ancestry White - Caucasian / European Heritage | 7 Participants | 64 Participants | 14 Participants | 17 Participants | 26 Participants |
| Sex: Female, Male Female | 5 Participants | 41 Participants | 10 Participants | 12 Participants | 14 Participants |
| Sex: Female, Male Male | 2 Participants | 31 Participants | 5 Participants | 7 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 31 | 0 / 19 | 0 / 15 |
| other Total, other adverse events | 7 / 7 | 30 / 31 | 17 / 19 | 15 / 15 |
| serious Total, serious adverse events | 1 / 7 | 0 / 31 | 1 / 19 | 0 / 15 |
Outcome results
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day180(U-B), unknown at baseline and within at Day180(U-W), unknown at baseline and above at Day180(U-A), below at baseline and below at Day180(B-B), below at baseline and within at Day180(B-W),below at baseline and above at Day180(B-A), within at baseline and below at Day180(W-B),within at baseline and within at Day180(W-W), within at baseline and above at Day180(W-A),above at baseline and below at Day180(A-B),above at baseline and within at Day180(A-W),above at baseline and above at Day180(A-A).
Time frame: At Day 180
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented and with available results at Day 180.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH,B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT,U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 16 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 9 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH,B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT,U-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT,U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH,B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 9 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 4 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT,U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH,B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day360(U-B), unknown at baseline and within at Day360(U-W), unknown at baseline and above at Day360(U-A), below at baseline and below at Day360(B-B), below at baseline and within at Day360(B-W),below at baseline and above at Day360(B-A), within at baseline and below at Day360(W-B),within at baseline and within at Day360(W-W), within at baseline and above at Day360(W-A),above at baseline and below at Day360(A-B),above at baseline and within at Day360(A-W),above at baseline and above at Day360(A-A).
Time frame: At Day 360
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented and with available results at Day 360.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC,B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 18 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC,B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 18 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 18 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC,B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 7 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC,B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cells \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 1 (U-B), unknown at baseline and within at Day 1 (U-W), unknown at baseline and above at Day 1 (U-A), below at baseline and below at Day 1 (B-B), below at baseline and within at Day 1 (B-W), below at baseline and above at Day 1(B-A), within at baseline and below at Day 1 (W-B), within at baseline and within at Day 1(W-W), within at baseline and above at Day 1(W-A), above at baseline and below at Day 1(A-B), above at baseline and within at Day 1 (A-W), above at baseline and above at Day 1(A-A)
Time frame: At Day 1
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 1.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 5 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 9 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | Hpg, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HgL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/ Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 3 (U-B), unknown at baseline and within at Day 3 (U-W), unknown at baseline and above at Day 3 (U-A), below at baseline and below at Day 3 (B-B), below at baseline and within at Day 3 (B-W), below at baseline and above at Day 3(B-A), within at baseline and below at Day 3 (W-B), within at baseline and within at Day 3(W-W), within at baseline and above at Day 3(W-A), above at baseline and below at Day 3(A-B), above at baseline and within at Day 3(A-W), above at baseline and above at Day 3(A-A).
Time frame: At Day 3
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 3.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 10 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 6 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/ Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 7 (U-B), unknown at baseline and within at Day 7 (U-W), unknown at baseline and above at Day 7 (U-A), below at baseline and below at Day 7 (B-B), below at baseline and within at Day 7 (B-W), below at baseline and above at Day 7(B-A), within at baseline and below at Day 7 (W-B), within at baseline and within at Day 7(W-W), within at baseline and above at Day 7(W-A), above at baseline and below at Day 7(A-B), above at baseline and within at Day 7(A-W), above at baseline and above at Day 7(A-A).
Time frame: At Day 7
Population: The analysis was performed on the Total Vaccinated cohort which which included all subjects with at least one study vaccine administration documented and with available results at Day 7.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 15 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 30(U-B), unknown at baseline and within at Day30(U-W), unknown at baseline and above at Day 30(U-A), below at baseline and below at Day30(B-B), below at baseline and within at Day30(B-W), below at baseline and above at Day 30(B-A), within at baseline and below at Day 30 (W-B), within at baseline and within at Day 30(W-W), within at baseline and above at Day30(W-A), above at baseline and below at Day30(A-B), above at baseline and within at Day30(A-W), above at baseline and above at Day30(A-A).
Time frame: At Day 30
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 30.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 5 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 10 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 31(U-B), unknown at baseline and within at Day31(U-W), unknown at baseline and above at Day 31(U-A), below at baseline and below at Day31(B-B), below at baseline and within at Day31(B-W), below at baseline and above at Day 31(B-A), within at baseline and below at Day 31(W-B), within at baseline and within at Day 31(W-W), within at baseline and above at Day31(W-A), above at baseline and below at Day31(A-B), above at baseline and within at Day31(A-W), above at baseline and above at Day31(A-A).
Time frame: At Day 31
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 31.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 17 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 9 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 7 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 7 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 3 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 33(U-B), unknown at baseline and within at Day33(U-W), unknown at baseline and above at Day 33(U-A), below at baseline and below at Day33(B-B), below at baseline and within at Day33(B-W), below at baseline and above at Day 33 (B-A), within at baseline and below at Day 33(W-B), within at baseline and within at Day 33(W-W), within at baseline and above at Day33(W-A), above at baseline and below at Day33(A-B), above at baseline and within at Day33(A-W), above at baseline and above at Day33(A-A).
Time frame: At Day 33
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 33.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 14 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 10 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 18 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 37(U-B), unknown at baseline and within at Day37(U-W), unknown at baseline and above at Day 37(U-A), below at baseline and below at Day37(B-B), below at baseline and within at Day37(B-W), below at baseline and above at Day 37(B-A), within at baseline and below at Day 37(W-B), within at baseline and within at Day 37(W-W), within at baseline and above at Day37(W-A), above at baseline and below at Day37(A-B), above at baseline and within at Day37(A-W), above at baseline and above at Day37(A-A).
Time frame: At Day 37
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 37.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 6 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 5 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 8 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Laboratory Abnormalities
Haematological/Biochemical parameters assessed were haemoglobin level \[HgL\], red blood cell \[RBC\], white blood cell \[WBC\], lymphocyte \[LYM\], neutrophil \[NEU\], eosinophil \[EOS\], reticulocyte \[RET\], platelet count \[PLC\], haptoglobin \[Hpg\], prothrombin time \[PT\] and partial thromboplastin time \[PTT\]. alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], creatinine \[CRE\], lactate dehydrogenase \[LDH\] and bilirubin direct or total \[BLD/BLT\].Values were: unknown at baseline and below at Day 60(U-B), unknown at baseline and within at Day60(U-W), unknown at baseline and above at Day 60(U-A), below at baseline and below at Day60(B-B), below at baseline and within at Day60(B-W), below at baseline and above at Day60(B-A), within at baseline and below at Day 60(W-B), within at baseline and within at Day 60(W-W), within at baseline and above at Day60(W-A), above at baseline and below at Day60(A-B), above at baseline and within at Day60(A-W), above at baseline and above at Day60(A-A).
Time frame: At Day 60
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented and with available results at Day 60.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 20 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 16 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 6 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 13 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 11 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 16 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, W-A | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-W | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LDH, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-W | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLD, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PLC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, W-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-A | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | WBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-W | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-W | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RBC, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | LYM, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PTT, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | PT, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-W | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | AST, B-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-B | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, W-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-W | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, U-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | BLT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | EOS, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, W-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | ALT, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | CRE, A-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HGL, B-A | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | NEU, A-B | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | HPG, B-W | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Laboratory Abnormalities | RET, A-W | 0 Participants |
Primary
Number of Subjects With Haematological and Biochemical Results by Maximum Grade
Parameters analysed were ALT, activated partial thromboplastin time \[APTT\], AST, total bilirubin \[TB\], CRE, EOS, haemoglobin decrease \[HgD\], LYM, NEU, platelets \[PLA\], PT, white blood cells decrease \[WBCD\] and white blood cells increase \[WBCI\]. Assessed grades were: Unknown \[UG\], grade 0 \[G0\] = no grade, 1 \[G1\] = mild grade, 2 \[G2\] = moderate grade, 3 \[G3\] = severe grade, 4 \[G4\] = potentially life threatening and overall grading \[GTotal\]. Parameter grade combinations expressed were: parameter plus UG/G0/1/2/3/4/Total at baseline versus grading G0/1/2/3/4/Total from Day 1 up to Day 60, for the same parameter, e.g. ALT G0-G2.
Time frame: From Day 1 to Day 60
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 9 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 9 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 6 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 3 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 15 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 6 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 4 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 4 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 10 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 4 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
Primary
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Day 0 to Day 360
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 60 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 360 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 360 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 60 | 0 Participants |
| Placebo Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 60 | 0 Participants |
| Placebo Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 360 | 1 Participants |
| Bexsero Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 60 | 0 Participants |
| Bexsero Group | Number of Subjects With Serious Adverse Events (SAEs) | Up to Day 360 | 0 Participants |
Primary
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)\] gastrointestinal symptoms (gastro) \[nausea, vomiting, diarrhoea and/or abdominal pain\] and headache. Any = occurrence of the symptom regardless of intensity grade and relationship to the vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort which included all subjects with at least one study vaccine administration documented, who had filled in their symptom sheets.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 2 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 1 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Across doses | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 2 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 1 | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fever Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Across doses | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fever Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 1 | 3 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Headache Across doses | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Across doses | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 1 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Headache Across doses | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 2 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Across doses | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 2 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 2 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 2 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Across doses | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Across doses | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 2 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fever Across doses | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Across doses | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fever Across doses | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 2 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 2 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Across doses | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 2 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 1 | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Headache Across doses | 16 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 2 | 10 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Across doses | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 2 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 1 | 14 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 2 | 10 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Headache Across doses | 16 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Gastro Across doses | 7 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 2 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 1 | 14 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 1 | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 1 | 8 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 1 | 8 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 1 | 6 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 1 | 6 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 1 | 8 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 1 | 8 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 2 | 6 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 2 | 6 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 2 | 4 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 2 | 4 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 2 | 5 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 2 | 5 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 2 | 1 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 2 | 1 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Across doses | 9 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Across doses | 9 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Gastro Across doses | 9 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Gastro Across doses | 9 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Headache Across doses | 10 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Headache Across doses | 10 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Any Fever Across doses | 1 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited General Symptoms | Related Fever Across doses | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 2 | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 2 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fever Across doses | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Gastro Across doses | 4 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 2 | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 2 | 9 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Gastro Dose 1 | 3 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 2 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 2 | 9 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Dose 1 | 8 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Gastro Across doses | 4 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 1 | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fever Across doses | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Headache Across doses | 12 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 1 | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 1 | 10 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 1 | 10 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Headache Across doses | 12 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fever Dose 2 | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fever Dose 2 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Gastro Dose 1 | 3 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Across doses | 11 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fever Dose 2 | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Headache Dose 2 | 9 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Gastro Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Fatigue Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Grade 3 Headache Dose 2 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Headache Dose 2 | 9 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Any Fatigue Dose 1 | 8 Participants |
| Bexsero Group | Number of Subjects With Solicited General Symptoms | Related Fatigue Across doses | 11 Participants |
Primary
Number of Subjects With Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site. All solicited local symptoms are considered as related to the vaccination.
Time frame: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented, who had filled in their symptom sheets.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Across doses | 4 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 1 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 2 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Across doses | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 1 | 23 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Across doses | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Across doses | 27 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Across doses | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 2 | 19 Participants |
| GSK3389245A_HD Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 1 | 1 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 1 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 2 | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Pain Across doses | 1 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Redness Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Across doses | 0 Participants |
| Placebo Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 1 | 15 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Across doses | 4 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 2 | 3 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 2 | 2 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Redness Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Redness Across doses | 3 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Pain Dose 2 | 15 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Pain Dose 1 | 3 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Across doses | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 1 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Across doses | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Swelling Dose 2 | 0 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Across doses | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Pain Across doses | 15 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Any Swelling Dose 2 | 1 Participants |
| Bexsero Group | Number of Subjects With Solicited Local Symptoms | Grade 3 Redness Dose 2 | 1 Participants |
Primary
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset out-side the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 30-day (Days 0-29) post-vaccination period
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Unsolicited Adverse Events (AEs) | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Unsolicited Adverse Events (AEs) | 21 Participants |
| Placebo Group | Number of Subjects With Unsolicited Adverse Events (AEs) | 14 Participants |
| Bexsero Group | Number of Subjects With Unsolicited Adverse Events (AEs) | 12 Participants |
Secondary
Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers
Serum neutralizing antibody titers were reported as the inverse of the serum dilution which yielded a 60% reduction in the number of viral plaques compared to virus control without serum (Estimated Dilution: ED60). Antibody titers were expressed as Geometric Mean Titers (GMTs).
Time frame: At pre-vaccination (Day 0), post-Dose 1 (Day 30) and post-Dose 2 (Day 60)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, i.e. those who were included in the Total Vaccinated Cohort and who received at least one dose of study vaccine.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| GSK3389245A_LD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 0) | 605.9 Titers |
| GSK3389245A_LD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 60) | 847.4 Titers |
| GSK3389245A_LD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 30) | 1474.1 Titers |
| GSK3389245A_HD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 0) | 519.4 Titers |
| GSK3389245A_HD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 60) | 1211.3 Titers |
| GSK3389245A_HD Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 30) | 1293.1 Titers |
| Placebo Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 30) | 492.4 Titers |
| Placebo Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 0) | 346.1 Titers |
| Placebo Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 60) | 347.3 Titers |
| Bexsero Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 0) | 409.4 Titers |
| Bexsero Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 60) | 376.9 Titers |
| Bexsero Group | Anti-respiratory Syncytial Virus (RSV) Neutralizing Antibodies Titers | Anti-RSV, (Day 30) | 493.8 Titers |
Secondary
Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC)
IgG/IgA antibody specific B-cells/ expressed as B-cells per million cells, were determined by the ELISpot assay.
Time frame: At pre-vaccination (Day 0) and post-Dose 1 (Day 7, Day 30) and post-Dose 2 (Day 37, Day 60)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, i.e. those who were included in the Total Vaccinated Cohort and who received at least one dose of study vaccine.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 0) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 7) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 30) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 37) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 60) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 0) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 7) | 45 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 30) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 37) | 1 B-cells/million cells |
| GSK3389245A_LD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 60) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 30) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 37) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 37) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 60) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 0) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 7) | 133.3 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 60) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 30) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 0) | 1 B-cells/million cells |
| GSK3389245A_HD Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 7) | 16.7 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 30) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 7) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 60) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 0) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 37) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 0) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 37) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 7) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 60) | 1 B-cells/million cells |
| Placebo Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 30) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 60) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 30) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 0) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 60) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 7) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 7) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 30) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 37) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgA, (Day 0) | 1 B-cells/million cells |
| Bexsero Group | Frequency of Anti-F Immunoglobulin g (IgG) and/or Immunoglobulin A (IgA) Antibody Secreting B-cells (ASC) | Memory B-cell IgG, (Day 37) | 1 B-cells/million cells |
Secondary
Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells
Interferon-gamma specific T-cells, expressed as T-cells per (/) million cells, were determined by the Enzyme Linked ImmunoSpot (ELISpot) assay.
Time frame: At pre-vaccination (Day 0) and post-Dose 1 (Day 7, Day 30) and post-Dose 2 (Day 37, Day 60)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, i.e. those who were included in the Total Vaccinated Cohort and who received at least one dose of study vaccine.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 0) | 33.3 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 7) | 3.3 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 37) | 20.5 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 30) | 1.7 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 60) | 11.7 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 0) | 10 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 37) | 18 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 7) | 28.3 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 37) | 8.8 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 60) | 20 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 0) | 21.7 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 30) | 1 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 7) | 3.3 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 60) | 15 T-cells/million cells |
| GSK3389245A_LD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 30) | 5 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 30) | 31.7 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 7) | 21.7 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 60) | 70.8 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 37) | 37.5 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 7) | 94.2 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 0) | 11.7 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 30) | 36.7 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 60) | 20 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 30) | 108.3 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 7) | 25 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 60) | 34.2 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 37) | 50 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 0) | 6.7 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 37) | 75 T-cells/million cells |
| GSK3389245A_HD Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 0) | 35 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 30) | 13.3 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 0) | 15 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 7) | 20 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 30) | 41.7 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 37) | 33.3 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 60) | 52.5 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 0) | 2.5 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 7) | 6.7 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 37) | 5.8 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 60) | 15 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 0) | 5 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 7) | 3.3 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 30) | 18.3 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 37) | 10.8 T-cells/million cells |
| Placebo Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 60) | 24.2 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 7) | 3.3 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 7) | 36.7 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 7) | 11.7 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 0) | 5 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 60) | 48.3 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 0) | 23.3 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 30) | 19.2 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 37) | 35 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV F, (Day 30) | 41.7 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 60) | 20 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 60) | 10 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 37) | 6.7 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 37) | 18.3 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV N, (Day 0) | 10 T-cells/million cells |
| Bexsero Group | Frequency of RSV Viral Protein F, N, M2-1 Specific Interferon-gamma (IFN-γ) Secreting T-cells | RSV M2-1, (Day 30) | 7.5 T-cells/million cells |
Secondary
Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value
Pre-defined cut-off values was higher than or equal to (≥) 8 ED60.
Time frame: At pre-vaccination (Day 0), post-Dose 1 (Day 30) and post-Dose 2 (Day 60)
Population: The analysis was performed on the According-To-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects, i.e. those who were included in the Total Vaccinated Cohort and who received at least one dose of study vaccine.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 0) | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 60) | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 30) | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 0) | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 60) | 26 Participants |
| GSK3389245A_HD Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 30) | 26 Participants |
| Placebo Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 30) | 18 Participants |
| Placebo Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 0) | 18 Participants |
| Placebo Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 60) | 18 Participants |
| Bexsero Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 0) | 15 Participants |
| Bexsero Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 60) | 15 Participants |
| Bexsero Group | Number of Subjects With Anti-RSV Neutralizing Antibodies Above the Cut-off Value | ANTI-RSV, (Day 30) | 15 Participants |
Secondary
Number of Subjects With Haematological and Biochemical Results by Maximum Grade
Parameters analysed were ALT, activated partial thromboplastin time \[APTT\], AST, total bilirubin \[TB\], CRE, EOS, haemoglobin decrease \[HgD\], LYM, NEU, platelets \[PLA\], PT, white blood cells decrease \[WBCD\] and white blood cells increase \[WBCI\]. Assessed grades were: Unknown \[UG\], grade 0 \[G0\] = no grade, 1 \[G1\] = mild grade, 2 \[G2\] = moderate grade, 3 \[G3\] = severe grade, 4 \[G4\] = potentially life threatening and overall grading \[GTotal\]. Parameter grade combinations expressed were: parameter plus UG/G0/1/2/3/4/Total at baseline versus grading G0/1/2/3/4/Total from Day 1 up to Day 360, for the same parameter, e.g. ALT G0-G2.
Time frame: From Day 1 up to Day 360
Population: The analysis was performed on the Total Vaccinated cohort, which included all subjects with at least one study vaccine administration documented.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 2 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 5 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 6 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 7 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 1 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| GSK3389245A_LD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 30 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 22 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 5 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 9 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 3 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 28 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 8 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 31 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 1 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 24 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 4 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 25 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 6 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 29 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 2 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 21 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| GSK3389245A_HD Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 9 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 4 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 14 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 5 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 19 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 5 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 17 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 1 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 2 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 5 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 18 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 12 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| Placebo Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G2 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G0 | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G1 | 4 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G2 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G0 | 15 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | AST, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G1 | 5 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, G4-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G0 | 12 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G1 | 5 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | NEU, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G1 | 3 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G1 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G0 | 9 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCD, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G0 | 14 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G0 | 11 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G2 | 1 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | EOS, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G3-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G0-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, GTotal-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PLA, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | WBCI, G0-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, G1-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G0 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | TB, G1-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G1 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G4 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | LYM, GTotal-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | HgD, G0-G0 | 9 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G2 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G1-G1 | 2 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | ALT, GTotal-G0 | 13 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | APTT, G4-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | PT, UG-G3 | 0 Participants |
| Bexsero Group | Number of Subjects With Haematological and Biochemical Results by Maximum Grade | CRE, GTotal-G0 | 15 Participants |